Global eye care company Alcon has announced an expansion in its line of ophthalmic products. These products, which include mydriatic, cycloplegic, diagnostic and anesthetic products, have been transferred from Alcon’s parent company, Novartis.
The products offered in the portfolio include:
- ISOPTO® Atropine (atropine sulfate ophthalmic solution) 1%, indicated for mydriasis (dilation of the pupil), cycloplegia (paralysis of the ciliary muscle of the eye), and penalization of the healthy eye in the treatment of amblyopia, a condition where vision in one or both eyes does not develop properly during childhood
- CYCLOGYL® (cyclopentolate hydrochloride ophthalmic solution, USP), an anticholinergic used to produce mydriasis and cycloplegia
- MYDRIACYL® (tropicamide ophthalmic solution, USP), an anticholinergic indicated for mydriasis and cycloplegia for diagnostic procedures
- CYCLOMYDRIL® (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution), indicated for the production of mydriasis
- FLUORESCITE® (fluorescein injection, USP) 10%, indicated in diagnostic fluorescein angiography (examination by X-ray of blood or lymph vessels) or angioscopy of the retina and iris vasculature
- Tetracaine Hydrochloride Ophthalmic Solution 0.5% STERI-UNIT®, an ester local anesthetic indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic
The portfolio of products is available now and can be purchased through authorized wholesalers and distributors. ISOPTO® Atropine 1% Solution is also available for purchase through Alcon Customer Service. To learn more, visit www.Alcon.com/Products.